Gilead

Foster City, United States Founded: 1987 • Age: 39 yrs Acquired By Citadel
Developer of medicines to treat HIVAIDS, liver diseases, cancer others
Request Access

About Gilead

Gilead is a company based in Foster City (United States) founded in 1987 was acquired by Citadel in October 2016.. The company has 17,600 employees as of December 31, 2024. Gilead has completed 18 acquisitions, including Arresto BioSciences, CGI Pharmaceuticals and CV Therapeutics. Gilead offers products and services including Antiviral Medicines, Oncology Drugs, and Inflammation Treatments. Gilead operates in a competitive market with competitors including Merck, Roivant Sciences, AbbVie, Lilly and Vertex Pharmaceuticals, among others.

  • Headquarter Foster City, United States
  • Employees 17600 as on 31 Dec, 2024
  • Stage Public
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Gilead Sciences, Inc.
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $28.73 B
    6.17
    as on Dec 31, 2024
  • Net Profit
    $480 M
    -91.53
    as on Dec 31, 2024
  • EBITDA
    $13.43 B
    7.96
    as on Dec 31, 2024
  • Latest Funding Round
    $290 K (USD), Post-IPO

    Jan 27, 2025

  • Investors
  • Employee Count
    17600

    as on Dec 31, 2024

  • Investments & Acquisitions
  • Acquired by
    Citadel

    (Oct 15, 2016)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Gilead

Gilead is a publicly listed company on the NASDAQ with ticker symbol GILD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: NASDAQ · Ticker: GILD . Sector: Health technology · USA

Products & Services of Gilead

Gilead offers a comprehensive portfolio of products and services, including Antiviral Medicines, Oncology Drugs, and Inflammation Treatments. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treatments for HIV, viral hepatitis, and emerging viruses

Therapies for cancer and related conditions

Medicines for inflammatory diseases and disorders

People of Gilead
Headcount 10000+
Employee Profiles 879
Board Members and Advisors 9
Employee Profiles
People
Rebecca Gledhill
Senior Manager, People Partner EMEA
People
Erin Burkhart
Senior Vice President, Controller & Chief Accounting Officer
People
Marcelo Kabbach
Procurement Solutions Excellence
People
Jaymin Mehta
Vice President, Global Commercial Head Of Liver, Inflammation, Covid-19, And Established Products

Unlock access to complete

Board Members and Advisors
people
Sandra J. Horning
Director
people
Ted W. Love
Director

Unlock access to complete

Funding Insights of Gilead

  • Total Funding
  • Total Rounds 5
  • Last Round Post-IPO — $290,000
  • First Round

    (01 Jul 2010)

  • Investors Count 8
Date Amount Transaction Name Valuation Lead Investors Investors
Jan, 2025 Amount Post-IPO - Gilead Valuation

investors

Jul, 2020 Amount Grant - Gilead Valuation

investors

Jan, 2020 Amount Grant - Gilead Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Gilead

Gilead has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Wealth Enhancement, DriveWealth and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Multiple sectors including healthcare are invested in by IFM Investors.
Founded Year Domain Location
Cloud-based API solutions for embedded investing are provided online.
Founded Year Domain Location
Investment management services are offered by Bellevue in Switzerland.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Gilead

Gilead has strategically engaged in corporate development activities, having acquired 18 companies. Notable acquisitions include Arresto BioSciences, CGI Pharmaceuticals and CV Therapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Small-molecule therapeutics for immuno-oncology diseases are developed.
2021
Developer of therapeutics for auto-immune diseases
2019
CAR T-cell immunotherapies for cancer and diseases are developed.
2016
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Gilead

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Gilead Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Gilead

Gilead operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, AbbVie, Lilly and Vertex Pharmaceuticals, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Pharmaceutical products are manufactured and marketed worldwide.
domain founded_year HQ Location
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
domain founded_year HQ Location
Biopharmaceutical research and drug development are conducted globally by AbbVie.
domain founded_year HQ Location
Traditional pharmaceutical medicines are developed for multiple health fields.
domain founded_year HQ Location
Developer of drugs for the treatment of multiple disorders
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Gilead

Frequently Asked Questions about Gilead

When was Gilead founded?

Gilead was founded in 1987 and raised its 1st funding round 23 years after it was founded.

Where is Gilead located?

Gilead is headquartered in Foster City, United States. It is registered at Foster City, California, United States.

How many employees does Gilead have?

As of Dec 31, 2024, the latest employee count at Gilead is 17,600.

What is the annual revenue of Gilead?

Annual revenue of Gilead is $28.73B as on Dec 31, 2024.

What does Gilead do?

Founded in 1987 and headquartered in Foster City, United States, Gilead operates as a research-based biopharmaceutical company. Innovative medicines are discovered, developed, and commercialized to address unmet medical needs in HIVAIDS, liver diseases, and cancer. Key developments include the Lenacapavir capsid inhibitor for HIV and the Selgantolimod TLR-8 agonist for HBV. In 2022, annual revenues of 27.28 billion and net profit of 4.59 billion were recorded.

Who are the top competitors of Gilead?

Gilead's top competitors include Merck, Roivant Sciences and AbbVie.

What products or services does Gilead offer?

Gilead offers Antiviral Medicines, Oncology Drugs, and Inflammation Treatments.

Is Gilead publicly traded?

Yes, Gilead is publicly traded on NASDAQ under the ticker symbol GILD.

How many acquisitions has Gilead made?

Gilead has made 18 acquisitions, including Arresto BioSciences, CGI Pharmaceuticals, and CV Therapeutics.

Who are Gilead's investors?

Gilead has 9 investors. Key investors include Wealth Enhancement, DriveWealth, Citadel, Bellevue, and European Union.

What is Gilead's ticker symbol?

The ticker symbol of Gilead is GILD on NASDAQ.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available